File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: A randomized controlled study

TitleThree-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: A randomized controlled study
Authors
Issue Date2001
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2001, v. 15 n. 6, p. 843-849 How to Cite?
AbstractAim: To compare the efficacy and tolerability of a 3-day quadruple therapy with a standard 7-day triple therapy in eradicating Helicobacter pylori infection and healing duodenal ulcers. Methods: Patients with H. pylori-positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM-7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB-3). No pre- or post-treatment acid suppression was used. Follow-up endoscopy was performed at week 6. Results: A total of 118 patients were recruited. Sixty patients in the LCM-7 group and 53 patients in the LCMB-3 group returned for endoscopy. Intention-to-treat eradication rates were 87% and 86% (P = 0.94) and per protocol eradication rates were 87% and 94% (P = 0.29) in the LCM-7 and LCMB-3 groups, respectively. Per protocol and intention-to-treat ulcer healing rates were 98% and 98% in LCM-7 and 100% and 91% in LCMB-3, respectively. There were no significant differences in efficacy in relation to the initial metronidazole and clarithromycin susceptibility. Significant reduction in the duration of side-effects was found in the LCMB-3 group. Conclusion: The 3-day quadruple therapy is highly effective, better tolerated and can be considered as a first-line therapy in duodenal ulcer management.
Persistent Identifierhttp://hdl.handle.net/10722/78422
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorWang, WHen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorLau, GKKen_HK
dc.contributor.authorFung, FMYen_HK
dc.contributor.authorKung, NNSen_HK
dc.contributor.authorChu, KMen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorHu, WHCen_HK
dc.contributor.authorHu, FLen_HK
dc.contributor.authorLiu, XGen_HK
dc.contributor.authorChan, CKen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorHui, WMen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2010-09-06T07:42:42Z-
dc.date.available2010-09-06T07:42:42Z-
dc.date.issued2001en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2001, v. 15 n. 6, p. 843-849en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78422-
dc.description.abstractAim: To compare the efficacy and tolerability of a 3-day quadruple therapy with a standard 7-day triple therapy in eradicating Helicobacter pylori infection and healing duodenal ulcers. Methods: Patients with H. pylori-positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM-7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB-3). No pre- or post-treatment acid suppression was used. Follow-up endoscopy was performed at week 6. Results: A total of 118 patients were recruited. Sixty patients in the LCM-7 group and 53 patients in the LCMB-3 group returned for endoscopy. Intention-to-treat eradication rates were 87% and 86% (P = 0.94) and per protocol eradication rates were 87% and 94% (P = 0.29) in the LCM-7 and LCMB-3 groups, respectively. Per protocol and intention-to-treat ulcer healing rates were 98% and 98% in LCM-7 and 100% and 91% in LCMB-3, respectively. There were no significant differences in efficacy in relation to the initial metronidazole and clarithromycin susceptibility. Significant reduction in the duration of side-effects was found in the LCMB-3 group. Conclusion: The 3-day quadruple therapy is highly effective, better tolerated and can be considered as a first-line therapy in duodenal ulcer management.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.en_HK
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen_HK
dc.subject.meshAdministration, Oralen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntacids - administration & dosage - therapeutic useen_HK
dc.subject.meshAnti-Bacterial Agents - administration & dosage - therapeutic useen_HK
dc.subject.meshAnti-Infective Agents - administration & dosage - adverse effects - pharmacologyen_HK
dc.subject.meshClarithromycin - administration & dosage - therapeutic useen_HK
dc.subject.meshDrug Administration Scheduleen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshDuodenal Ulcer - drug therapy - microbiology - pathologyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMetronidazole - administration & dosage - therapeutic useen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOmeprazole - administration & dosage - adverse effects - analogs & derivatives - pharmacologyen_HK
dc.subject.meshOrganometallic Compounds - therapeutic useen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleThree-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: A randomized controlled studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-2813&volume=15&spage=843&epage=850&date=2001&atitle=Three-day+Lansoprazole+quadruple+therapy+for+Helicobacter+pylori-positive+duodenal+ulcers:+a+randomized+controlled+studyen_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.emailChu, KM: chukm@hkucc.hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.identifier.authorityChu, KM=rp00435en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1046/j.1365-2036.2001.00999.xen_HK
dc.identifier.pmid11380322-
dc.identifier.scopuseid_2-s2.0-0034982544en_HK
dc.identifier.hkuros68520en_HK
dc.identifier.hkuros72113-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034982544&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue6en_HK
dc.identifier.spage843en_HK
dc.identifier.epage849en_HK
dc.identifier.isiWOS:000168747600011-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridWang, WH=23390847100en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.scopusauthoridFung, FMY=7003833944en_HK
dc.identifier.scopusauthoridKung, NNS=6603573627en_HK
dc.identifier.scopusauthoridChu, KM=7402453538en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridHu, WHC=25932937100en_HK
dc.identifier.scopusauthoridHu, FL=7202526345en_HK
dc.identifier.scopusauthoridLiu, XG=26643623200en_HK
dc.identifier.scopusauthoridChan, CK=7404813824en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridHui, WM=7103196477en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats